| Ticker Details |
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins.
|
| IPO Date: |
July 6, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$8.9B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.47 | 3.23%
|
| Avg Daily Range (30 D): |
$1.41 | 2.14%
|
| Avg Daily Range (90 D): |
$1.57 | 2.87%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.77M |
| Avg Daily Volume (30 D): |
2.1M |
| Avg Daily Volume (90 D): |
2.2M |
| Trade Size |
| Avg Trade Size (Sh.): |
110 |
| Avg Trade Size (Sh.) (30 D): |
67 |
| Avg Trade Size (Sh.) (90 D): |
68 |
| Institutional Trades |
| Total Institutional Trades: |
5,706 |
| Avg Institutional Trade: |
$3.69M |
| Avg Institutional Trade (30 D): |
$9.66M |
| Avg Institutional Trade (90 D): |
$7.6M |
| Avg Institutional Trade Volume: |
.11M |
| Avg Institutional Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$6.12M |
| Avg Closing Trade (30 D): |
$30.48M |
| Avg Closing Trade (90 D): |
$19.56M |
| Avg Closing Volume: |
188.49K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$1.56
|
$.22
|
$-.18
|
|
Diluted EPS
|
$1.53
|
$.22
|
$-.18
|
|
Revenue
|
$1.09B
|
$264.03M
|
$256.47M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$233.57M
|
$28.24M
|
$16.12M
|
|
Operating Income / Loss
|
$300.57M
|
$40.81M
|
$44.11M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$147.75M
|
$-24.91M
|
$96.76M
|
|
PE Ratio
|
41.61
|
|
|
| Splits |
|
Nov 17, 2011
|
1:10
|
|
Jan 15, 2004
|
1:65
|
|
|
|
